Based in Copenhagen, Denmark, with North American operations based in Fairfax, Virginia, Immudex provides MHC Dextramers for the monitoring of antigen-specific T cells. Under an agreement with the US Cancer Immunotherapy Consortium (CIC) and the European Cancer Immunotherapy Consortium (CIMT), Immudex also provides MHC Multimer and Elispot proficiency panel services worldwide. Immudex’s MHC Dextramer® products are utilized for the quantification or sorting of antigen-specific T cells in life science research, in vitro diagnostics, as well as the development of immunotherapeutics and vaccines. The primary focus is research-use-only products for the immune monitoring of immunotherapy development, and monitoring of CMV cellular immunity in transplant and other immune-deficient patients. Our FDA 510(k) cleared and CE-marked Dextramer CMV Kit is utilized for the quantification of CMV-specific T cells during immune reconstitution post stem cell transplant. dCode DNA tagged Dextramer reagents enable massive multiplexing of antigen-specific T cell detection. Simultaneous detection of over 1000 CD8 T cell specificities in a single, small blood sample has been achieved.
"Very professional team. Orders are always complete in a timely manner. The team keeps us updated on the progress, and is willing to work with us on difficult to produce custom reagents."
Immudex has not received any endorsements.